Novartis Pavillon in Basel Announces European Commission Approval for Itvisma® in Spinal Muscular Atrophy
The European Commission has granted approval for Itvisma® (onasemnogene abeparvovec), marking a significant regulatory milestone for patients with 5q spinal muscular atrophy (SMA). Announced by Novartis, the decision extends gene replacement therapy options across a broader patient demographic within the European Union, encompassing children aged two and older, teenagers, and adults with a bi-allelic mutation in the SMN1 gene.
As the first gene replacement therapy authorized for this wider age group in the EU, Itvisma offers a distinct clinical approach compared to ongoing dosing strategies.
Advancing Treatments for the SMA Community in Basel and Beyond
Spinal muscular atrophy is a rare genetic neuromuscular condition triggered by a mutated or missing SMN1 gene, which is essential for producing the protein required for normal muscle movement, swallowing, and breathing. Without adequate protein, motor neurons face irreversible loss.
Itvisma addresses this genetic root cause directly through a fixed, one-time intrathecal dose designed to replace the faulty gene and maintain functional protein expression without requiring age or weight adjustments. Clinical evaluations, such as the STEER study published in Nature Medicine, demonstrated measurable motor function improvements for both treatment-naive and pre-treated individuals over a 52-week period.
Exploring Medical Innovation in Basel
Visitors interested in the intersection of healthcare, scientific research, and future therapies can explore ongoing insights through cultural and public exhibition venues in the city. To plan your next visit, check out the map view or browse museums to discover more about what is on offer across Basel with Musemap (musemap.art).
